• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    AstraZeneca PLC – ADR to Join the NASDAQ-100 Index Beginning February 22, 2022

    2/10/22 5:00:00 PM ET
    $AZN
    $NDAQ
    $XLNX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Bankers/Brokers/Service
    Finance
    Get the next $AZN alert in real time by email

    NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced that AstraZeneca PLC – ADR (NASDAQ:AZN), will become a component of the NASDAQ-100 Index® (NASDAQ:NDX) and the NASDAQ-100 Equal Weighted Index (NASDAQ:NDXE) prior to market open on Tuesday, February 22, 2022. AstraZeneca PLC – ADR will replace Xilinx, Inc. (NASDAQ:XLNX) in the NASDAQ-100 Index® and the NASDAQ-100 Equal Weighted Index.

    For more information about the company, go to https://www.astrazeneca.com.

    About Nasdaq

    Nasdaq (NASDAQ:NDAQ) is a global technology company serving the capital markets and other industries. Our diverse offering of data, analytics, software and services enables clients to optimize and execute their business vision with confidence. To learn more about the company, technology solutions and career opportunities, visit us on LinkedIn, on Twitter @Nasdaq, or at www.nasdaq.com.

    Media Contact

    Emily Pan

    [email protected]

    +1 (646) 637-3964

    Issuer & Investor Contact

    Index Client Services

    [email protected]

    The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular financial product or an overall investment strategy. Neither The NASDAQ OMX Group, Inc. nor any of its affiliates makes any recommendation to buy or sell any financial product or any representation about the financial condition of any company or fund. Statements regarding Nasdaq's proprietary indexes are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.

    - NDAQG -



    Primary Logo

    Get the next $AZN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AZN
    $NDAQ
    $XLNX

    CompanyDatePrice TargetRatingAnalyst
    Nasdaq Inc.
    $NDAQ
    11/20/2025$110.00Equal-Weight → Overweight
    Morgan Stanley
    AstraZeneca PLC
    $AZN
    10/27/2025Buy
    Jefferies
    AstraZeneca PLC
    $AZN
    10/16/2025Hold → Sell
    Deutsche Bank
    Nasdaq Inc.
    $NDAQ
    7/25/2025$115.00Neutral → Buy
    UBS
    Nasdaq Inc.
    $NDAQ
    4/17/2025$91.00Neutral → Buy
    Redburn Atlantic
    AstraZeneca PLC
    $AZN
    4/15/2025$75.00Outperform
    Exane BNP Paribas
    Nasdaq Inc.
    $NDAQ
    4/8/2025$74.00Overweight → Equal-Weight
    Morgan Stanley
    AstraZeneca PLC
    $AZN
    2/13/2025Neutral → Buy
    UBS
    More analyst ratings

    $AZN
    $NDAQ
    $XLNX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, CSO Skule Jeremy covered exercise/tax liability with 4,127 shares, decreasing direct ownership by 5% to 78,742 units (SEC Form 4)

    4 - NASDAQ, INC. (0001120193) (Issuer)

    12/9/25 4:03:39 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    EVP & CFO Youngwood Sarah covered exercise/tax liability with 16,506 shares, decreasing direct ownership by 22% to 59,291 units (SEC Form 4)

    4 - NASDAQ, INC. (0001120193) (Issuer)

    12/9/25 4:00:36 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    EVP, CPO Smith Bryan Everard sold $419,611 worth of shares (4,633 units at $90.57), decreasing direct ownership by 7% to 57,670 units (SEC Form 4)

    4 - NASDAQ, INC. (0001120193) (Issuer)

    12/3/25 4:08:00 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    $AZN
    $NDAQ
    $XLNX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    NASDAQ upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded NASDAQ from Equal-Weight to Overweight and set a new price target of $110.00

    11/20/25 7:58:08 AM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    Jefferies resumed coverage on AstraZeneca

    Jefferies resumed coverage of AstraZeneca with a rating of Buy

    10/27/25 8:41:53 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AstraZeneca downgraded by Deutsche Bank

    Deutsche Bank downgraded AstraZeneca from Hold to Sell

    10/16/25 8:19:10 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    $NDAQ
    $XLNX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Zollar Alfred W bought $203,970 worth of shares (2,542 units at $80.24), increasing direct ownership by 5% to 49,293 units (SEC Form 4)

    4 - NASDAQ, INC. (0001120193) (Issuer)

    11/14/24 4:29:16 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    Torgeby Johan bought $705,880 worth of shares (14,000 units at $50.42), increasing direct ownership by 165% to 22,466 units (SEC Form 4)

    4 - NASDAQ, INC. (0001120193) (Issuer)

    10/25/23 4:02:10 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    $AZN
    $NDAQ
    $XLNX
    SEC Filings

    View All

    SEC Form 6-K filed by AstraZeneca PLC

    6-K - ASTRAZENECA PLC (0000901832) (Filer)

    12/4/25 1:48:33 PM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Nasdaq Inc.

    8-K - NASDAQ, INC. (0001120193) (Filer)

    12/1/25 4:17:01 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    SEC Form 144 filed by Nasdaq Inc.

    144 - NASDAQ, INC. (0001120193) (Subject)

    12/1/25 4:03:13 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    $AZN
    $NDAQ
    $XLNX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nasdaq Announces End-of-Month Open Short Interest Positions in Nasdaq Stocks as of Settlement Date November 28, 2025

    NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- At the end of the settlement date of November 28, 2025, short interest in 3,453 Nasdaq Global MarketSM securities totaled 14,879,370,342 shares compared with 14,632,128,542 shares in 3,414 Global Market issues reported for the prior settlement date of November 14, 2025. The November short interest represents 2.22 days compared with 2.16 days for the prior reporting period. Short interest in 1,698 securities on The Nasdaq Capital MarketSM totaled 3,311,934,829 shares at the end of the settlement date of November 28, 2025, compared with 3,326,683,612 shares in 1,697 securities for the previous reporting period. This represents a 1.00 day average d

    12/9/25 4:05:00 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    Walmart Debuts on Nasdaq, Marking Its First Day of Trading

    Company Rings in a New Era with Nasdaq Opening Bell Ceremony Walmart Inc. (NASDAQ:WMT) today announced it has completed the listing transfer of its common stock and bonds to Nasdaq and will begin trading, marking a new chapter in the company's 63-year history of growth, innovation, and long-term value creation for shareholders. This move follows an evaluation of several factors, including trading execution, brand alignment, and a shared focus on technology-driven innovation to support Walmart's position as the world's leading omnichannel retailer. As Walmart continues to define and lead the future of global retail, the company is confident that Nasdaq provides the optimal market platform

    12/9/25 7:00:00 AM ET
    $NDAQ
    $WMT
    Investment Bankers/Brokers/Service
    Finance
    Department/Specialty Retail Stores
    Consumer Discretionary

    DESTINY-Ovarian01 Phase 3 Trial of ENHERTU® Initiated as First-Line Maintenance Therapy in Patients with HER2 Expressing Advanced Ovarian Cancer

    The first patient has been dosed in the randomization phase of the DESTINY-Ovarian01 phase 3 trial evaluating ENHERTU® (trastuzumab deruxtecan) in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy in patients with HER2 expressing (IHC 3+/2+/1+) advanced high-grade epithelial ovarian cancer following treatment with first-line platinum-based chemotherapy in combination with bevacizumab. DESTINY-Ovarian01 is being conducted in collaboration with the European Network of Gynecological Oncological Trial Groups (ENGOT), with the Spanish cooperative group (GEICO) as the lead ENGOT group, The GOG Foundation, Inc. (GOG-F) and Asia-Pacific Gynecologic Oncol

    12/9/25 7:00:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    $NDAQ
    $XLNX
    Leadership Updates

    Live Leadership Updates

    View All

    Vistagen Appoints Nick Tressler as Chief Financial Officer

    Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Nick Tressler as Chief Financial Officer (CFO), effective today, December 1, 2025. "I am excited to welcome Nick to Vistagen as our CFO. His financial and strategic acumen and extensive operational experience in the biopharmaceutical industry will be instrumental as we accelerate into our next phase," said President and Chief Executive Officer of Vistagen, Shawn Singh. "I look forward to his contributions to our leadership team and the po

    12/1/25 8:30:00 AM ET
    $AZN
    $SENS
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    Puro.earth Secures €11 M Series B Financing Led by Nasdaq with Participation from Fortum Innovation & Venturing to strengthen its supplier infrastructure

    HELSINKI, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Puro.earth, a leading carbon-crediting platform for engineered carbon dioxide removal (CDR), today announced it has raised €11 million in a Series B funding round led by Nasdaq with participation from Fortum Innovation & Venturing. Puro.earth will deploy this funding to strengthen the infrastructure that supports its best-in-class certification journey for suppliers. Key initiatives include enabling more frequent issuance of high-integrity carbon removal credits, facilitating offtake agreements, and advancing open integration of digital measurement, reporting, and verification (dMRV) tools. The new investment builds on a period of strong gr

    9/4/25 7:00:00 AM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    Thomson Reuters Corp to Join the Nasdaq-100 Index® Beginning July 28, 2025

    NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced that Thomson Reuters Corp (NASDAQ:TRI), will become a component of the Nasdaq-100 Index® (NASDAQ:NDX®) and the Nasdaq-100 Equal Weighted™ Index (NASDAQ:NDXE) prior to market open on Monday, July 28, 2025. Thomson Reuters Corp will replace ANSYS, Inc. (NASDAQ:ANSS) in the Nasdaq-100 Index® and the Nasdaq-100 Equal Weighted™ Index. ANSYS, Inc. will also be removed from the Nasdaq-100 Tech Sector™ Index (NASDAQ:NDXT), the Nasdaq-100 Technology Sector Market-Cap Weighted™ Index (NDXTMC™), the Nasdaq-100 Technology Sector Adjusted Market-Cap Weighted™ Index (NDXT10™), the Nasdaq-100 ESG™ Index (NASDAQ:ND

    7/18/25 8:00:00 PM ET
    $ANSS
    $NDAQ
    $TRI
    Computer Software: Prepackaged Software
    Technology
    Investment Bankers/Brokers/Service
    Finance

    $AZN
    $NDAQ
    $XLNX
    Financials

    Live finance-specific insights

    View All

    Walmart Debuts on Nasdaq, Marking Its First Day of Trading

    Company Rings in a New Era with Nasdaq Opening Bell Ceremony Walmart Inc. (NASDAQ:WMT) today announced it has completed the listing transfer of its common stock and bonds to Nasdaq and will begin trading, marking a new chapter in the company's 63-year history of growth, innovation, and long-term value creation for shareholders. This move follows an evaluation of several factors, including trading execution, brand alignment, and a shared focus on technology-driven innovation to support Walmart's position as the world's leading omnichannel retailer. As Walmart continues to define and lead the future of global retail, the company is confident that Nasdaq provides the optimal market platform

    12/9/25 7:00:00 AM ET
    $NDAQ
    $WMT
    Investment Bankers/Brokers/Service
    Finance
    Department/Specialty Retail Stores
    Consumer Discretionary

    Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension

    Submission based on positive BaxHTN Phase III trial results which demonstrated statistically significant and clinically meaningful reduction in systolic blood pressure in patients with resistant or uncontrolled hypertension If approved, baxdrostat could be the first aldosterone synthase inhibitor to receive regulatory authorization AstraZeneca's New Drug Application (NDA) for baxdrostat has been accepted for Priority Review by the US Food and Drug Administration (FDA) in the US for the treatment of adult patients with hard-to-control (uncontrolled or treatment resistant) hypertension as an add-on to other antihypertensive medicines when these do not provide adequate lowering of blood pres

    12/2/25 9:18:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Baxdrostat demonstrated a statistically significant and highly clinically meaningful placebo-adjusted reduction of 14.0 mmHg in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension in the Bax24 Phase III trial

    Baxdrostat demonstrated a statistically significant placebo-adjusted reduction of 13.9 mmHg in night-time ambulatory systolic blood pressure at 12 weeks with a safety profile consistent with the BaxHTN trial Full results presented at the American Heart Association Scientific Sessions 2025 Positive full results from the Bax24 Phase III trial showed baxdrostat demonstrated a statistically significant and highly clinically meaningful reduction in ambulatory 24-hour average systolic blood pressure (SBP) compared with placebo at 12 weeks. Patients with treatment-resistant hypertension (rHTN) received baxdrostat 2mg or placebo on top of standard of care.1 Efficacy was observed throughout the

    11/9/25 4:33:00 PM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    $NDAQ
    $XLNX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Nasdaq Inc.

    SC 13G/A - NASDAQ, INC. (0001120193) (Subject)

    11/12/24 3:53:01 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    SEC Form SC 13G filed by Nasdaq Inc.

    SC 13G - NASDAQ, INC. (0001120193) (Subject)

    11/8/24 10:52:39 AM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    Amendment: SEC Form SC 13G/A filed by Nasdaq Inc.

    SC 13G/A - NASDAQ, INC. (0001120193) (Subject)

    11/4/24 1:18:47 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance